TheEdgeResearch
Home / Stocks / ORINY

Orion Oyj (ORINY)

OTC Healthcare Drug Manufacturers - General
$56.16 ▼ -1.07%
Market Cap
$31.50B
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
0.29
52-Wk Range
33.625-58.15
CEO
Aino Anna Liisa Hurme
Country
FI
Currency
USD

Orion Oyj operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Espoo, UU, FI. The stock last traded at $56.16, down 1.07% on the session, giving a market capitalisation of $31.50B. On trailing twelve-month figures it carries a trailing P/E of 21.45, a net margin of 30.3%. Its beta of 0.29 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
21.45
Price / Sales
6.47
Price / Book
10.11
EV / EBITDA
15.80
Gross margin
67.4%
Operating margin
38.2%
Net margin
30.3%
Return on equity
—
Debt / equity
0.09
Current ratio
2.72
Dividend yield
1.8%
Payout ratio
36.8%
Company profile
Exchange
Other OTC
Employees
4,029
IPO date
2014-12-09
Headquarters
Espoo, UU, FI
About Orion Oyj

Orion Oyj is a global pharmaceutical company engaged in the research, development, manufacturing, and commercialization of human and veterinary medicines, alongside active pharmaceutical ingredients (APIs). Its market reach extends across Finland, the Nordic countries, wider Europe, North America, and other international territories. The company's human health division offers both prescription drugs and self-care products. Its key prescription medications include Nubeqa for prostate cancer treatment, dexdor and Precedex for intensive care sedation, and therapies like Stalevo and Comtess/Comtan for Parkinson's disease. Other significant human products are Simdax for acute decompensated heart failure and Fareston for breast cancer. Orion also provides a comprehensive suite of Easyhaler-branded drugs, such as Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol, all designed to treat asthma and chronic obstructive pulmonary disease (COPD). In the animal health sector, Orion offers veterinary pharmaceuticals including Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. Beyond its own product line, the company manufactures APIs for both generic and proprietary drugs and provides contract manufacturing services. Orion also acts as a distributor, marketing and selling veterinary medicines produced by other international companies. Its customer base is broad, serving various healthcare providers and professionals, including specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as direct consumers with pets. Orion Oyj fosters strategic partnerships, notably with Propeller Health to embed connectivity into its Easyhaler® portfolio for asthma and COPD, and a research collaboration and license agreement with Alligator Bioscience AB (publ) focusing on the discovery and advancement of innovative bispecific antibody cancer therapeutics. Founded in 1917, Orion Oyj is headquartered in Espoo, Finland.

Comparable companies

Orion Oyj is most often compared with the following Healthcare names:

ALPMYAZNBIIBDSNKYGILDGSKMRKOPHLYPFESNY
More research on ORINY
ORINY technical analysis ORINY TheEdge Score Compare against peers
Open full interactive analysis & DCF →